

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 March 2024 (07.03.2024)



(10) International Publication Number
WO 2024/044847 A1

(51) International Patent Classification:

C07D 403/06 (2006.01) C07D 401/04 (2006.01)
A61K 31/404 (2006.01) C07D 401/14 (2006.01)
A61K 31/407 (2006.01) C07D 405/14 (2006.01)
A61K 31/427 (2006.01) C07D 409/14 (2006.01)
A61K 31/454 (2006.01) C07D 417/14 (2006.01)
A61K 31/4439 (2006.01) C07D 491/056 (2006.01)
A61P 25/00 (2006.01)

(21) International Application Number:

PCT/CA2023/051143

(22) International Filing Date:

29 August 2023 (29.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/401,847 29 August 2022 (29.08.2022) US

(71) Applicant: MINDSET PHARMA INC. [CA/CA]; 217
Queen Street West, Suite 401, Toronto, Ontario M5V 0R2
(CA).



(72) Inventor: SLASSI, Abdelmalik; 4780 Fulwell Road, Mississauga, Ontario L5M 7J7 (CA).

(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.;
Scotia Plaza, 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2 (CA).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,


(54) Title: INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO




(Q1)




(Q2)




(Q3)



(Q4)



(Q5)



(Q6)

(57) Abstract: The present application relates to methods of activating serotonin receptors in a cell using indoline derivatives of general Formula (I) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, as well as to treating diseases, disorders or conditions by activation of a serotonin receptors in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses and CNS disorders. The present application also relates to novel indoline derivatives and to compositions and uses thereof. Wherein Q is selected from (Q1), (Q2), (Q3), (Q4) (Q5) and (Q6).

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*